A practical approach to connective tissue disease-associated lung disease

Diffuse Lung Disease: A Practical Approach: Second Edition

Volumn 9781441997715, Issue , 2012, Pages 217-237

  Fischer, Aryeh ^a   Du Bois, Roland M ^b  

^a DEPARTMENT OF MEDICINE   (United States)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

Author keywords

Collagen vascular disease; Connective tissue disease; Interstitial lung disease; Lung disease; Lung dominant connective tissue disease

Indexed keywords

EID: 84939122653     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9771-5_12     Document Type: Chapter

References (114)

1. Lamblin C, Bergoin C, Saelens T, Wallaert B. Interstitial lung diseases in collagen vascular diseases. Eur Respir J Suppl. 2001;32:69s-80.
2. Strange C, Highland KB. Interstitial lung disease in the patient who has connective tissue disease. Clin Chest Med. 2004;25(3):549-59, vii.
3. Wiedemann HP, Matthay RA. Pulmonary manifestations of the collagen vascular diseases. Clin Chest Med. 1989;10(4):677-722.
4. Frankel SK, Brown KK. Collagen vascular diseases of the lung. Clin Pulm Med. 2006;13(1):25-36.
5. Huggett MT, Armstrong R. Adalimumab-associated pulmonary fi brosis. Rheumatology (Oxford). 2006; 45(10):1312-3.
6. Peno-Green L, Lluberas G, Kingsley T, Brantley S. Lung injury linked to etanercept therapy. Chest. 2002; 122(5):1858-60.
7. Villeneuve E, St-Pierre A, Haraoui B. Interstitial pneumonitis associated with infl iximab therapy. J Rheumatol. 2006;33(6):1189-93.
8. Ognenovski VM, Ojo TC, Fox DA. Etanerceptassociated pulmonary granulomatous infl ammation in patients with rheumatoid arthritis. J Rheumatol. 2008; 35(11):2279-82.
9. Zimmer C, Beiderlinden M, Peters J. Lethal acute respiratory distress syndrome during anti-TNF-alpha therapy for rheumatoid arthritis. Clin Rheumatol. 2006;25(3):430-2.
10. Hirabayashi Y, Shimizu H, Kobayashi N, Kudo K. Lefl unomide-induced pneumonitis in a patient with rheumatoid arthritis. Intern Med. 2006;45(10):689-91.
11. Jenks KA, Stamp LK, O'Donnell JL, Savage RL, Chapman PT. Lefl unomide-associated infections in rheumatoid arthritis. J Rheumatol. 2007;34(11):2201-3.
12. Martin N, Innes JA, Lambert CM, Turnbull CM, Wallace WA. Hypersensitivity pneumonitis associated with lefl unomide therapy. J Rheumatol. 2007; 34(9):1934-7.
13. Ochi S, Harigai M, Mizoguchi F, Iwai H, Hagiyama H, Oka T, et al. Lefl unomide-related acute interstitial pneumonia in two patients with rheumatoid arthritis: autopsy fi ndings with a mosaic pattern of acute and organizing diffuse alveolar damage. Mod Rheumatol. 2006;16(5):316-20.
14. Sakai F, Noma S, Kurihara Y, Yamada H, Azuma A, Kudoh S, et al. Lefl unomide-related lung injury in patients with rheumatoid arthritis: imaging features. Mod Rheumatol. 2005;15(3):173-9.
15. Sato T, Inokuma S, Sagawa A, Matsuda T, Takemura T, Otsuka T, et al. Factors associated with fatal outcome of lefl unomide-induced lung injury in Japanese patients with rheumatoid arthritis. Rheumatology (Oxford). 2009;48(10):1265-8.
16. Takeishi M, Akiyama Y, Akiba H, Adachi D, Hirano M, Mimura T. Lefl unomide induced acute interstitial pneumonia. J Rheumatol. 2005;32(6):1160-3.
17. Wong SP, Chu CM, Kan CH, Tsui HS, Ng WL. Successful treatment of lefl unomide-induced acute pneumonitis with cholestyramine wash-out therapy. J Clin Rheumatol. 2009;15(8):389-92.
18. Camus P. Drug induced infi ltrative lung diseases. 4th ed. Hamilton: BC Decker; 2003.
19. Imokawa S, Colby TV, Leslie KO, Helmers RA. Methotrexate pneumonitis: review of the literature and histopathological fi ndings in nine patients. Eur Respir J. 2000;15(2):373-81.
20. Suda T, Sato A, Toyoshima M, Imokawa S, Yoshitomi A, Tamura R, et al. Weekly low-dose methotrexate therapy for sarcoidosis. Intern Med. 1994;33(7): 437-40.
21. Heffner JE, Sahn SA. Salicylate-induced pulmonary edema. Clinical features and prognosis. Ann Intern Med. 1981;95(4):405-9.
22. Alarcon GS, Kremer JM, Macaluso M, Weinblatt ME, Cannon GW, Palmer WR, et al. Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med. 1997;127(5):356-64.
23. Kremer JM, Alarcon GS, Weinblatt ME, Kaymakcian MV, Macaluso M, Cannon GW, et al. Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum. 1997;40(10):1829-37.
24. Lynch DA, Quantitative CT. of fi brotic interstitial lung disease. Chest. 2007;131(3):643-4.
25. Lynch DA, Travis WD, Muller NL, Galvin JR, Hansell DM, Grenier PA, et al. Idiopathic interstitial pneumonias: CT features. Radiology. 2005;236(1): 10-21.
26. Tanaka N, Newell JD, Brown KK, Cool CD, Lynch DA. Collagen vascular disease-related lung disease: high-resolution computed tomography fi ndings based on the pathologic classifi cation. J Comput Assist Tomogr. 2004;28(3):351-60.
27. Hwang JH, Misumi S, Sahin H, Brown KK, Newell JD, Lynch DA. Computed tomographic features of idiopathic fi brosing interstitial pneumonia: comparison with pulmonary fi brosis related to collagen vascular disease. J Comput Assist Tomogr. 2009;33(3): 410-5.
28. Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP. Pulmonary function in patients receiving longterm low-dose methotrexate. Chest. 1996;109(4): 933-8.
29. Burton C, Kaczmarski R, Jan-Mohamed R. Interstitial pneumonitis related to rituximab therapy. N Engl J Med. 2003;348(26):2690-1. discussion 2690-1.
30. Hagiwara K, Sato T, Takagi-Kobayashi S, Hasegawa S, Shigihara N, Akiyama O. Acute exacerbation of preexisting interstitial lung disease after administration of etanercept for rheumatoid arthritis. J Rheumatol. 2007;34(5):1151-4.
31. Silver RM, Miller KS, Kinsella MB, Smith EA, Schabel SI. Evaluation and management of scleroderma lung disease using bronchoalveolar lavage. Am J Med. 1990;88(5):470-6.
32. Strange C, Bolster MB, Roth MD, Silver RM, Theodore A, Goldin J, et al. Bronchoalveolar lavage and response to cyclophosphamide in scleroderma interstitial lung disease. Am J Respir Crit Care Med. 2008;177(1):91-8.
33. Goh NS, Veeraraghavan S, Desai SR, Cramer D, Hansell DM, Denton CP, et al. Bronchoalveolar lavage cellular profi les in patients with systemic sclerosis-associated interstitial lung disease are not predictive of disease progression. Arthritis Rheum. 2007;56(6):2005-12.
34. Antoniou KM, Margaritopoulos G, Economidou F, Siafakas NM. Pivotal clinical dilemmas in collagen vascular diseases associated with interstitial lung involvement. Eur Respir J. 2009;33(4):882-96.
35. Bjoraker JA, Ryu JH, Edwin MK, Myers JL, Tazelaar HD, Schroeder DR, et al. Prognostic signifi cance of histopathologic subsets in idiopathic pulmonary fi brosis. Am J Respir Crit Care Med. 1998;157(1): 199-203.
36. Daniil ZD, Gilchrist FC, Nicholson AG, Hansell DM, Harris J, Colby TV, et al. A histologic pattern of nonspecifi c interstitial pneumonia is associated with a better prognosis than usual interstitial pneumonia in patients with cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med. 1999;160(3):899-905.
37. Nicholson AG, Colby TV, du Bois RM, Hansell DM, Wells AU. The prognostic signifi cance of the histologic pattern of interstitial pneumonia in patients presenting with the clinical entity of cryptogenic fi brosing alveolitis. Am J Respir Crit Care Med. 2000;162(6):2213-7.
38. Bouros D, Wells AU, Nicholson AG, Colby TV, Polychronopoulos V, Pantelidis P, et al. Histopathologic subsets of fi brosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med. 2002; 165(12):1581-6.
39. Park JH, Kim DS, Park IN, Jang SJ, Kitaichi M, Nicholson AG, et al. Prognosis of fi brotic interstitial pneumonia: idiopathic versus collagen vascular disease-related subtypes. Am J Respir Crit Care Med. 2007;175(7):705-11.
40. Fischer A, Swigris JJ, Groshong SD, Cool CD, Sahin H, Lynch DA, et al. Clinically signifi cant interstitial lung disease in limited scleroderma: histopathology, clinical features, and survival. Chest. 2008;134(3): 601-5.
41. Fischer A. Interstitial lung disease: a rheumatologist's perspective. J Clin Rheumatol. 2009;15(2): 95-9.
42. Cottin V. Interstitial lung disease: are we missing formes frustes of connective tissue disease? Eur Respir J. 2006;28(5):893-6.
43. Mittoo S, Gelber AC, Christopher-Stine L, Horton MR, Lechtzin N, Danoff SK. Ascertainment of collagen vascular disease in patients presenting with interstitial lung disease. Respir Med. 2009;103(8): 1152-8.
44. Tzelepis GE, Toya SP, Moutsopoulos HM. Occult connective tissue diseases mimicking idiopathic interstitial pneumonias. Eur Respir J. 2008;31(1): 11-20.
45. Homma Y, Ohtsuka Y, Tanimura K, Kusaka H, Munakata M, Kawakami Y, et al. Can interstitial pneumonia as the sole presentation of collagen vascular diseases be differentiated from idiopathic interstitial pneumonia? Respiration. 1995;62(5):248-51.
46. Fischer A, Swigris JJ, du Bois RM, Lynch DA, Downey GP, Cosgrove GP, et al. Anti-synthetase syndrome in ANA and anti-Jo-1 negative patients presenting with idiopathic interstitial pneumonia. Respir Med. 2009;103(11):1719-24.
47. Fischer A, Swigris JJ, du Bois RM, Groshong SD, Cool CD, Sahin H, et al. Minor salivary gland biopsy to detect primary Sjogren syndrome in patients with interstitial lung disease. Chest. 2009;136(4):1072-8.
48. Fischer A, Meehan RT, Feghali-Bostwick CA, West SG, Brown KK. Unique characteristics of systemic sclerosis sine scleroderma-associated interstitial lung disease. Chest. 2006;130(4):976-81.
49. Fukuoka J, Lesile KO. Practical pulmonary pathology. A diagnostic approach. 1st ed. Philadelphia, PA: Churchill-Livingstone; 2005.
50. Travis WD, Colby TV, Koss MN, Rosadode-Christenson ML, Muller NL, King Jr. TE. Nonneoplastic disorders of the lower respiratory tract. 1st ed. Washington, DC: American Registry of Pathology and the Armed Forces Institute of Pathology; 2002.
51. Leslie KO, Trahan S, Gruden J. Pulmonary pathology of the rheumatic diseases. Semin Respir Crit Care Med. 2007;28(4):369-78.
52. Song JW, Do KH, Kim MY, Jang SJ, Colby TV, Kim DS. Pathologic and radiologic differences between idiopathic and collagen vascular disease-related usual interstitial pneumonia. Chest. 2009;136(1): 23-30.
53. Fujita J, Ohtsuki Y, Yoshinouchi T, Yamadori I, Bandoh S, Tokuda M, et al. Idiopathic non-specifi c interstitial pneumonia: as an "autoimmune interstitial pneumonia". Respir Med. 2005;99(2):234-40.
54. Kinder BW, Collard HR, Koth L, Daikh DI, Wolters PJ, Elicker B, et al. Idiopathic nonspecifi c interstitial pneumonia: lung manifestation of undifferentiated connective tissue disease? Am J Respir Crit Care Med. 2007;176(7):691-7.
55. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classifi cation criteria. Clin Exp Rheumatol. 1999;17(5):615-20.
56. Vaz CC, Couto M, Medeiros D, Miranda L, Costa J, Nero P, et al. Undifferentiated connective tissue disease: a seven-center cross-sectional study of 184 patients. Clin Rheumatol. 2009;28(8):915-21.
57. Fischer A, West SG, Swigris JJ, Brown KK, du Bois RM. Connective tissue disease-associated interstitial lung disease: a call for clarifi cation. Chest. 2010;138(2):251-6.
58. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum. 2005;35(1):35-42.
59. Fischer A, Brown KK, Frankel SK. Treatment of connective tissue disease related interstitial lung disease. Clin Pulm Med. 2009;16(2):74-80.
60. Walker WC, Wright V. Diffuse interstitial pulmonary fi brosis and rheumatoid arthritis. Ann Rheum Dis. 1969;28(3):252-9.
61. Holgate ST, Glass DN, Haslam P, Maini RN, Turner-Warwick M. Respiratory involvement in systemic lupus erythematosus. A clinical and immunological study. Clin Exp Immunol. 1976;24(3):385-95.
62. Sullivan WD, Hurst DJ, Harmon CE, Esther JH, Agia GA, Maltby JD, et al. A prospective evaluation emphasizing pulmonary involvement in patients with mixed connective tissue disease. Medicine (Baltimore). 1984;63(2):92-107.
63. Steen VD, Medsger Jr. TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum. 1998;41(9):1613-9.
64. Reinhold-Keller E, Kekow J, Schnabel A, Schmitt WH, Heller M, Beigel A, et al. Infl uence of disease manifestation and antineutrophil cytoplasmic antibody titer on the response to pulse cyclophosphamide therapy in patients with Wegener's granulomatosis. Arthritis Rheum. 1994;37(6):919-24.
65. Hoyles RK, Ellis RW, Wellsbury J, Lees B, Newlands P, Goh NS, et al. A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fi brosis in scleroderma. Arthritis Rheum. 2006;54(12):3962-70.
66. Tashkin DP, Elashoff R, Clements PJ, Goldin J, Roth MD, Furst DE, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med. 2006;354(25):2655-66.
67. Tashkin DP, Elashoff R, Clements PJ, Roth MD, Furst DE, Silver RM, et al. Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease. Am J Respir Crit Care Med. 2007;176(10):1026-34.
68. Silver RM, Warrick JH, Kinsella MB, Staudt LS, Baumann MH, Strange C. Cyclophosphamide and low-dose prednisone therapy in patients with systemic sclerosis (scleroderma) with interstitial lung disease. J Rheumatol. 1993;20(5):838-44.
69. Steen VD, Lanz Jr. JK, Conte C, Owens GR, Medsger Jr. TA. Therapy for severe interstitial lung disease in systemic sclerosis. A retrospective study. Arthritis Rheum. 1994;37(9):1290-6.
70. White B, Moore WC, Wigley FM, Xiao HQ, Wise RA. Cyclophosphamide is associated with pulmonary function and survival benefi t in patients with scleroderma and alveolitis. Ann Intern Med. 2000; 132(12):947-54.
71. Goldin J, Elashoff R, Kim HJ, Yan X, Lynch D, Strollo D, et al. Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fi brosis on serial thoracic high-resolution CT scan than placebo: fi ndings from the scleroderma lung study. Chest. 2009;136(5):1333-40.
72. Furst DE, Clements, PJ. Immunosuppressives. In: Hochberg MC SA, Smolen JS, Weinblatt ME, Weisman MH, editors. Rheumatology. III ed. Spain: Mosby; 2003. p. 439-48.
73. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Effiffcacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med. 2000;343(16):1156-62.
74. Swigris JJ, Olson AL, Fischer A, Lynch DA, Cosgrove GP, Frankel SK, et al. Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue diseaserelated interstitial lung disease. Chest. 2006;130(1): 30-6.
75. Liossis SN, Bounas A, Andonopoulos AP. Mycophenolate mofetil as fi rst-line treatment improves clinically evident early scleroderma lung disease. Rheumatology (Oxford). 2006;45(8):1005-8.
76. Zamora AC, Wolters PJ, Collard HR, Connolly MK, Elicker BM, Webb WR, et al. Use of mycophenolate mofetil to treat scleroderma-associated interstitial lung disease. Respir Med. 2008;102(1):150-5.
77. Gerbino AJ, Goss CH, Molitor JA. Effect of mycophenolate mofetil on pulmonary function in scleroderma-associated interstitial lung disease. Chest. 2008;133(2):455-60.
78. Felson DT, Anderson J. Evidence for the superiority of immunosuppressive drugs and prednisone over prednisone alone in lupus nephritis. Results of a pooled analysis. N Engl J Med. 1984;311(24): 1528-33.
79. Nicholls A, Snaith ML, Maini RN, Scott JT. Proceedings: controlled trial of azathioprine in rheumatoid vasculitis. Ann Rheum Dis. 1973;32(6): 589-91.
80. Yazici H, Pazarli H, Barnes CG, Tuzun Y, Ozyazgan Y, Silman A, et al. A controlled trial of azathioprine in Behcet's syndrome. N Engl J Med. 1990;322(5): 281-5.
81. Nadashkevich O, Davis P, Fritzler M, Kovalenko W. A randomized unblinded trial of cyclophosphamide versus azathioprine in the treatment of systemic sclerosis. Clin Rheumatol. 2006;25(2):205-12.
82. Dheda K, Lalloo UG, Cassim B, Mody GM. Experience with azathioprine in systemic sclerosis associated with interstitial lung disease. Clin Rheumatol. 2004;23(4):306-9.
83. Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fi brosis. N Engl J Med. 2005;353(21):2229-42.
84. Stolk JN, Boerbooms AM, de Abreu RA, de Koning DG, van Beusekom HJ, Muller WH, et al. Reduced thiopurine methyltransferase activity and development of side effects of azathioprine treatment in patients with rheumatoid arthritis. Arthritis Rheum. 1998;41(10):1858-66.
85. Clunie GP, Lennard L. Relevance of thiopurine methyltransferase status in rheumatology patients receiving azathioprine. Rheumatology (Oxford). 2004;43(1):13-8.
86. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333(3): 137-41.
87. Wells G, Tugwell P. Cyclosporin A in rheumatoid arthritis: overview of effiffcacy. Br J Rheumatol. 1993;32 Suppl 1:51-6.
88. Clements PJ, Lachenbruch PA, Sterz M, Danovitch G, Hawkins R, Ippoliti A, et al. Cyclosporine in systemic sclerosis. Results of a forty-eight-week open safety study in ten patients. Arthritis Rheum. 1993;36(1):75-83.
89. BenEzra D, Cohen E, Chajek T, Friedman G, Pizanti S, de Courten C, et al. Evaluation of conventional therapy versus cyclosporine A in Behcet's syndrome. Transplant Proc. 1988;20(3 Suppl 4):136-43.
90. Oddis CV, Sciurba FC, Elmagd KA, Starzl TE. Tacrolimus in refractory polymyositis with interstitial lung disease. Lancet. 1999;353(9166):1762-3.
91. Wilkes MR, Sereika SM, Fertig N, Lucas MR, Oddis CV. Treatment of antisynthetase-associated interstitial lung disease with tacrolimus. Arthritis Rheum. 2005;52(8):2439-46.
92. Koopman WJ. Dawn of the era of biologics in the treatment of the rheumatic diseases. Arthritis Rheum. 2008;58(2 Suppl):S75-8.
93. Toussirot E, Wendling D. The use of TNF-alpha blocking agents in rheumatoid arthritis: an overview. Expert Opin Pharmacother. 2004;5(3):581-94.
94. Vassallo R, Matteson E, Thomas Jr. CF. Clinical response of rheumatoid arthritis-associated pulmonary fi brosis to tumor necrosis factor-alpha inhibition. Chest. 2002;122(3):1093-6.
95. Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. 2005;11(5):461-6.
96. Gasper WJ, Sweet MP, Golden JA, Hoopes C, Leard LE, Kleinhenz ME, et al. Lung transplantation in patients with connective tissue disorders and esophageal dysmotility. Dis Esophagus. 2008;21(7): 650-5.
97. Rosas V, Conte JV, Yang SC, Gaine SP, Borja M, Wigley FM, et al. Lung transplantation and systemic sclerosis. Ann Transplant. 2000;5(3):38-43.
98. Shitrit D, Amital A, Peled N, Raviv Y, Medalion B, Saute M, et al. Lung transplantation in patients with scleroderma: case series, review of the literature, and criteria for transplantation. Clin Transplant. 2009; 23(2):178-83.
99. Massad MG, Powell CR, Kpodonu J, Tshibaka C, Hanhan Z, Snow NJ, et al. Outcomes of lung transplantation in patients with scleroderma. World J Surg. 2005;29(11):1510-5.
100. Schachna L, Medsger Jr. TA, Dauber JH, Wigley FM, Braunstein NA, White B, et al. Lung transplantation in scleroderma compared with idiopathic pulmonary fi brosis and idiopathic pulmonary arterial hypertension. Arthritis Rheum. 2006;54(12):3954-61.
101. Brieva J. Cyclophosphamide-induced acute respiratory distress syndrome. Respirology. 2007;12(5): 769-73.
102. Spector JI, Zimbler H. Cyclophosphamide pneumonitis. N Engl J Med. 1982;307(4):251.
103. Malik SW, Myers JL, DeRemee RA, Specks U. Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med. 1996;154(6 Pt 1):1851-6.
104. Ryu JH, Krowka MJ, Pellikka PA, Swanson KL, McGoon MD. Pulmonary hypertension in patients with interstitial lung diseases. Mayo Clin Proc. 2007;82(3):342-50.
105. Arcasoy SM, Christie JD, Ferrari VA, Sutton MS, Zisman DA, Blumenthal NP, et al. Echocardiographic assessment of pulmonary hypertension in patients with advanced lung disease. Am J Respir Crit Care Med. 2003;167(5):735-40.
106. Steen V, Medsger Jr. TA. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement. Arthritis Rheum. 2003;48(2):516-22.
107. Steen VD. The lung in systemic sclerosis. J Clin Rheumatol. 2005;11(1):40-6.
108. Hachulla E, de Groote P, Gressin V, Sibilia J, Diot E, Carpentier P, et al. The three-year incidence of pulmonary arterial hypertension associated with systemic sclerosis in a multicenter nationwide longitudinal study in France. Arthritis Rheum. 2009;60(6):1831-9.
109. Hachulla E, Launay D, Mouthon L, Sitbon O, Berezne A, Guillevin L, et al. Is pulmonary arterial hypertension really a late complication of systemic sclerosis? Chest. 2009;136(5):1211-9.
110. Bull TM. Screening and therapy of pulmonary hypertension in systemic sclerosis. Curr Opin Rheumatol. 2007;19(6):598-603.
111. Olschewski H, Ghofrani HA, Walmrath D, Schermuly R, Temmesfeld-Wollbruck B, Grimminger F, et al. Inhaled prostacyclin and iloprost in severe pulmonary hypertension secondary to lung fi brosis. Am J Respir Crit Care Med. 1999;160(2):600-7.
112. Shapiro S. Management of pulmonary hypertension resulting from interstitial lung disease. Curr Opin Pulm Med. 2003;9(5):426-30.
113. Pipavath SJ, Lynch DA, Cool C, Brown KK, Newell JD. Radiologic and pathologic features of bronchiolitis. AJR Am J Roentgenol. 2005;185(2):354-63.
114. Denton CP, Pope JE, Peter HH, Gabrielli A, Boonstra A, van den Hoogen FH, et al. Long-term effects of bosentan on quality of life, survival, safety and tolerability in pulmonary arterial hypertension related to connective tissue diseases. Ann Rheum Dis. 2008; 67(9):1222-8.